Abstract: The present invention relates to a biocatalytic method of preparing a mono-acylated polyol catalyzed by triacylglycerol lipase mutants, as for example derived from Candida antarctica lipase B (CALB); a biocatalytic method of enantioselectively preparing an asymmetric mono-acylated polyol, catalyzed by the same enzyme mutants; as well as the use of a mutated triacylglycerol lipase in a method of preparing mono-acylated polyols. The invention also provides novel mutants, coding sequences thereof, and recombinant microorganisms carrying said coding sequences.

Abstract: The present invention relates to a biocatalytic method of preparing a mono-acylated polyol catalyzed by triacylglycerol lipase mutants, as for example derived from Candida antarctica lipase B (CALB); a biocatalytic method of enantioselectively preparing an asymmetric mono-acylated polyol, catalyzed by the same enzyme mutants; as well as the use of a mutated triacylglycerol lipase in a method of preparing mono-acylated polyols. The invention also provides novel mutants, coding sequences thereof, and recombinant microorganisms carrying said coding sequences.

Abstract: The present invention relates to a biocatalytic method of preparing a mono-acylated polyol catalyzed by triacyl-glycerol lipase mutants, as for example derived from Candida antarctica lipase B (CALB); a biocatalytic method of enantioselectively preparing an asymmetric mono-acylated polyol, catalyzed by the same enzyme mutants; as well as the use of a mutated triacylglycerol lipase in a method of preparing mono-acylated polyols. The invention also provides novel mutants, coding sequences thereof, and recombinant microorganisms carrying said coding sequences.

Abstract: The present invention relates to chromophores for selective staining of cells or cell parts comprising a fluorescent chromophore of the general formulae I The invention further comprises a method for cell sorting, a method for cell targeting, as well as a method for cell identification.

Abstract: The present invention relates to compounds for the treatment and prevention of disease that are linked to disturbances and defects in the secretory system. Such diseases include diarrhea, Menière's disease, various kinds of edema, and so on. The inventors have shown that the compound erucamide can be used for such treatment. Use of a compound according to the formula (I), wherein R1 is a saturated or partly unsaturated straight or branched alkyl chain comprising 15-28, or preferably 19-24, carbon atoms or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a pharmaceutical composition, to be used in the treatment of a mammal suffering from any of the conditions chosen from the group comprising; diarrhea, cerebral edema, Menières disease, ulcerative colitis or Crohn's disease.

Abstract: A method and composition is described for treating neurological diseases such as migraine, by influencing the nerve cells. This is achieved by optimizing the ability of the nerve cell gliacytes to transport taurine and the ability of the nerve cells to absorb taurine, by the external supply of amino acids occurring normally in the body. Preferred compositions include taurine, L-carnitine, zinc gluconate and calcium glycerophosphate.